Apnimed, Inc. Common Stock (APMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apnimed, Inc. Common Stock (APMD) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.81 Million) by net assets ($257.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Apnimed, Inc. Common Stock (APMD) market capitalisation for the company's overall valuation and market capitalisation.
Apnimed, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Apnimed, Inc. Common Stock for real-time trading data and today's change.
Apnimed, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apnimed, Inc. Common Stock ranked by their cash flow conversion efficiency. Review Apnimed, Inc. Common Stock leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senvest Capital Inc.
TO:SEC
|
0.074x |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
-0.055x |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
-0.003x |
|
Shandong Ruifeng Chemical Co Ltd
SHE:300243
|
-0.005x |
|
Criteo Sa
NASDAQ:CRTO
|
0.017x |
|
Diversified United Investment Ltd
AU:DUI
|
0.018x |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
0.097x |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
0.043x |
Annual Cash Flow Conversion Efficiency for Apnimed, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Apnimed, Inc. Common Stock from 2024 to 2025. Also see how large is Apnimed, Inc. Common Stock's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-372.78 Million | $-77.83 Million | 0.209x | -52.90% |
| 2024-12-31 | $-248.62 Million | $-110.21 Million | 0.443x | -- |
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambr… Read more